Amycretin (Novo Nordisk) (10mg)
Amycretin is an investigational dual GLP-1 and amylin receptor agonist by Novo Nordisk, in Phase 2 clinical trials (subcutaneous and oral forms) for obesity and type 2 diabetes. There is no approved indication or brand name. The 10mg/vial protocol is presented solely for educational/research purposes, based on published Phase 1b/2a clinical data.
Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer
How It Works
Amycretin is a **single-molecule co-agonist** that simultaneously activates the GLP-1 receptor and the amylin receptor (AMY1, AMY2, AMY3). The GLP-1 arm enhances glucose-dependent insulin secretion, suppresses glucagon, and slows gastric emptying. The amylinergic component adds further satiety via the area postrema of the brainstem and enhances the reduction of food intake. Unlike the combination of cagrilintide + semaglutide (CagriSema, two molecules), Amycretin merges both actions into **one peptide**, simplifying pharmacokinetics and allowing for an oral formulation with Novo Nordisk's SNAC technology.
Quick Start
- Reconstitution: 2.0 mL bacteriostatic water → 5 mg/mL.
- Investigational Dose Range (Phase 1b SC): 1.25 → 20 mg/week.
- Frequency: 1× weekly (subcutaneous arm).
- Status: Investigational — not approved by any regulatory authority.
- Storage: 2–8 °C after reconstitution, use within 28 days.
Dosing Table — Amycretin 10mg (1 mL = 5 mg/mL)
Route: Subcutaneous injection (investigational) | Frequency: 1× weekly
| Week | Dose | Units (per injection) |
|---|---|---|
| 1–4 | 1.25 mg | 25 Units (0.25 mL) |
| 5–8 | 2.5 mg | 50 Units (0.50 mL) |
| 9–12 | 5 mg | 100 Units (1.00 mL) |
| 13–20 | 10 mg | 2 × 100 Units (1.00 mL) |
| 21+ | 20 mg (max Phase 1b) | 4 × 100 Units (1.00 mL) |
The above reflects the escalation schedule of Phase 1b/2a clinical trials (NCT05669599 and related). There is no approved dosing for human use outside of a clinical protocol.
Related compounds
Reconstitution Steps
- Clean the vial stoppers with an alcohol pad.
- Withdraw 2.0 mL of bacteriostatic water.
- Inject slowly down the inner wall of the vial.
- Gently swirl until fully dissolved — do not shake.
- Refrigerate at 2–8 °C, protect from light.
Protocol Overview
- Dual GLP-1 / amylin agonist (single-molecule co-agonist).
- Being investigated as both a weekly subcutaneous injection and a daily oral tablet.
- In Phase 1b trials: average weight loss of ~13% at 12 weeks (SC, 20mg).
- In Phase 2 for T2DM: simultaneous improvement in glycemic control and weight.
- Not commercially available — only within approved clinical trials.
Dosing Protocol
- Start at 1.25 mg/week to minimize gastrointestinal symptoms.
- Gradual titration every 4 weeks.
- Maximum dosage in published trials: 20 mg/week (SC).
- Same day each week, with or without food.
- No approved maintenance regimen — under study.
- Break between cycles: No official washout protocol has been established. In research settings, a 4-week pause between cycles is reasonable, analogous to other weekly GLP-1 agonists.
Washout & Cycle Restart
When can I restart?
No official washout protocol has been established. In research settings, a 4-week pause between cycles is reasonable, analogous to other weekly GLP-1 agonists.
Minimum wait period: 4 weeks
Storage Instructions
- Lyophilized powder: refrigerate 2–8 °C, protect from light.
- Reconstituted: 2–8 °C, use within 28 days.
- Do not freeze.
Important Notes
- Investigational compound — no regulatory approval worldwide.
- The amylinergic component may increase gastrointestinal symptoms compared to GLP-1 mono-agonists.
- Combination with other GLP-1 agonists or amylin peptides is not recommended.
- Potential interactions with insulin/sulfonylureas — risk of hypoglycemia.
- This protocol is exclusively for educational/research purposes.
Regulatory Status
Amycretin is in ongoing Phase 2 development by Novo Nordisk in both subcutaneous and oral forms. It has not been approved by any regulatory authority and is not commercially available. All references to dosing and performance come from published clinical trial data and are presented for educational purposes only.
ClinicalTrials.gov — Amycretin trialsPotential Benefits & Side Effects
Potential Benefits:
- Dual action GLP-1 + amylin in a single molecule
- Potent weight loss in early trials (~13% in 12 weeks)
- Available as both oral & subcutaneous formulations under investigation
- Potentially faster weight loss compared to GLP-1 mono-agonists
- Parallel improvement of glycemic control in T2DM
Potential Side Effects:
- Nausea (very common, dose-dependent)
- Vomiting & anorexia (especially during titration)
- Diarrhea or constipation
- Potential hypoglycemia when combined with insulin/sulfonylureas
- Injection site reactions (SC formulation)
- Unknown long-term safety profile — under study
⚠️ Serious Warnings & Long-Term Risks
The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.
Potential thyroid C-cell risk
As an investigational GLP-1/amylin agonist, amycretin is monitored for class-effect issues related to GLP-1 pharmacology and thyroid safety.
📄 ClinicalTrials.gov NCT05669599Gastrointestinal tolerability under investigation
Early GLP-1/amylin data identify gastrointestinal tolerability as a key monitoring point during escalation.
📄 Lancet Phase 1 amycretin publicationReferences
- Novo Nordisk — Amycretin Phase 1 results (2024) — Single ascending dose Phase 1 of subcutaneous amycretin in obesity (Lancet, 2025).
View Source - Oral amycretin Phase 1b (2025) — Oral amycretin once-daily for obesity — Phase 1b results, Novo Nordisk press release.
View Source - GLP-1 / amylin co-agonism — Lutz TA. Amylin and GLP-1 receptor combination therapy: rationale and clinical perspectives. Diabetes Obes Metab. 2024.
View Source - ClinicalTrials.gov NCT05669599 — A research study of amycretin in people who are overweight or have obesity.
View Source - ADA 2024 Scientific Sessions — Amycretin Phase 1 data presentation, American Diabetes Association.
View Source
Recommended Supplements
Vitamin B12 (Methylcobalamin)
Vitamin D3 + K2
Omega-3 Fish Oil (EPA/DHA)
Protein / Collagen
Fiber Supplement (Psyllium)
External Sources & Regulatory Status
Regulatory Approvals
Obesity / Type 2 diabetes
Obesity / Type 2 diabetes
Research-only — Phase III ongoing
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
Continue Your Research
Explore tools and guides related to this protocol.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →